Sugi Predict

Sugi Predict / Targets / ITGB6

ITGB6

Integrin beta-6 · P18564 · ITGB6 on Sugi Atlas →

29,871 patent compounds predicted against ITGB6, 20,320 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL2833650 SCHEMBL2833650 0.84 20/20
SCHEMBL328002 SCHEMBL328002 0.59 20/20
SCHEMBL328047 SCHEMBL328047 0.58 20/20
SCHEMBL328145 SCHEMBL328145 0.56 20/20
SCHEMBL2838879 SCHEMBL2838879 0.82 19/20
SCHEMBL328013 SCHEMBL328013 0.66 19/20
SCHEMBL275846 SCHEMBL275846 0.54 19/20
SCHEMBL328036 SCHEMBL328036 0.52 19/20
SCHEMBL328144 SCHEMBL328144 0.52 19/20
SCHEMBL2440964 SCHEMBL2440964 0.52 19/20
SCHEMBL2232978 SCHEMBL2232978 0.52 19/20
SCHEMBL2232990 SCHEMBL2232990 0.52 19/20
SCHEMBL2836956 SCHEMBL2836956 1.00 18/20
SCHEMBL328153 SCHEMBL328153 0.69 18/20
SCHEMBL328135 SCHEMBL328135 0.67 18/20
SCHEMBL328204 SCHEMBL328204 0.62 18/20
SCHEMBL328040 SCHEMBL328040 0.61 18/20
SCHEMBL328149 SCHEMBL328149 0.60 18/20
SCHEMBL328048 SCHEMBL328048 0.60 18/20
SCHEMBL328157 SCHEMBL328157 0.59 18/20

Clinical trials — most relevant to ITGB6 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Outcomes of ICSI Cycles With and Without Letrozole PHASE4UNKNOWN
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer PHASE1/PHASE2COMPLETED
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease PHASE2UNKNOWN
A Pilot Study to Assess the Efficacy of Rituximab Therapy in Treatment Resistant FSGS PHASE2COMPLETED
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Myocardial Angiogenesis PHASE2COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
Molecularly Targeted Radionuclide Therapy Via the Integrin Alphavbeta6 PHASE1RECRUITING
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors EARLY_PHASE1NOT_YET_RECRUITING
Integrin α6-targeted SPECT Imaging of Breast Cancer EARLY_PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients EARLY_PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage nanCOMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Integrin αvβ6-targeted PET in Malignant Tumors nanRECRUITING
Early Regenerative Intervention for Post-Traumatic Osteoarthritis nanUNKNOWN
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
Clinical Pattern of Glanzemnn Thrombathenia in Children Attending Assiut University Children Hospital nanNOT_YET_RECRUITING
T Lymphocyte Subsets in Ulcerative Colitis nanNOT_YET_RECRUITING
In-vivo Thrombus Imaging With 18F-GP1, a Novel Platelet PET Radiotracer nanCOMPLETED
Integrins and Protocadherins in Glutamatergic Circuits: Identification of Common Signaling Pathways and Molecular Targets in Anxiety and Major Depressive Disorders (GAPsy) nanUNKNOWN
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ITGB6 binder may also engage these)

ProteinNameSimilarity
Q6AYF4 — 1.000 Q6AYF4 →
P18563 — 1.000 P18563 →
Q1RPR6 — 1.000 Q1RPR6 →
Q8SQB8 — 1.000 Q8SQB8 →
Q863C4 — 1.000 Q863C4 →
Q9Z0T9 — 1.000 Q9Z0T9 →
A2A863 — 0.988 A2A863 →
ITGB4 Integrin beta-4 0.987 landscape →
O54890 — 0.987 O54890 →
Q07441 — 0.984 Q07441 →
Q64632 — 0.983 Q64632 →
Q8R2H2 — 0.982 Q8R2H2 →
Q6DDW2 — 0.980 Q6DDW2 →
P26011 — 0.979 P26011 →
ITGB3 Integrin beta-3 0.979 landscape →
Q6DYE8 — 0.979 Q6DYE8 →
P43406 — 0.979 P43406 →
P61622 — 0.979 P61622 →
ITGB7 Integrin beta-7 0.979 landscape →
O70309 — 0.978 O70309 →
Q5RB89 — 0.978 Q5RB89 →
P12607 — 0.978 P12607 →
Q6DFX2 — 0.978 Q6DFX2 →
ITGB2 Integrin beta-2 0.977 landscape →
ITGB1 Integrin beta-1 0.977 landscape →
B0S5N4 — 0.977 B0S5N4 →
Q9HB63 — 0.976 Q9HB63 →
P26008 — 0.976 P26008 →
Q9UKX5 — 0.976 Q9UKX5 →
W8E7D1 — 0.976 W8E7D1 →